Telix Pharmaceuticals (TLX) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and commercial outlook

• 2026 strategy centers on investing in a robust therapeutics pipeline, with three late-stage clinical programs driving most investment.

• Commercial growth is expected through new product launches, notably Gozellix, and international expansion, with a focus on leveraging the commercial organization for multi-product delivery.

• Record revenue of AUD 804 million in the previous year, up 56% year-on-year, with 2026 guidance set at $950–$970 million, excluding unapproved products.

• RLS acquisition supports both current revenue and future radioligand therapy infrastructure, with ongoing investments in manufacturing and supply chain verticalization.

• International filings and expansion are underway, including Pixclara in Europe and China, and a bridging study in Japan.

Product pipeline and innovation

• Gozellix launch is expected to significantly impact ASP and market share, with a differentiated clinical and reimbursement profile compared to Illuccix.

• Ongoing product lifecycle management aims for continued innovation and new clinical capabilities, with new non-PSMA targets entering human trials.

• Pixclara and Zircaix filings are imminent, with regulatory issues addressed and near-term catalysts anticipated.

• Multiple label-expanding studies are planned, including a Bypass Biopsy Study that could double the U.S. prostate cancer imaging market.

Therapeutics pipeline and clinical development

• TLX591 (ProstACT Global) has completed Part One, meeting safety endpoints; global randomization is underway, with a futility analysis expected by Q4 this year.

• TLX250's main competitor is belzutifan, with the LUTEON trial targeting advanced metastatic patients and aiming for disease control.

• TLX101 interim analysis is planned for mid-next year, with strong early clinical responses and potential for early or conditional approval.

• TLX090 (bone palliation) is positioned for rapid regulatory approval due to its comparability to existing products and addresses unmet needs in pain management.

• The company is generating significant data across its therapy programs, aiming to shift market perception from diagnostics to a valued therapeutics business.